Hims & Hers Stock Stays Hot Amid Peptides Buzz
This image was generated by AI and may not depict real events.
Hims & Hers Health Inc's stock surged 4.5% to $25.52 after the FDA scheduled a meeting to consider adding peptides to a list for compounding pharmacies. The development could boost the telehealth company's access to a popular market.
Hims & Hers Health Inc's stock is up 4.5% to $25.52, driven by the FDA's announcement to consider peptides for compounding pharmacies. The telehealth company's shares have nearly doubled from their two-year low of $13.74. The stock is heavily shorted, with 34.5% of its float sold short. Analysts are watching for upgrades, with 12 of 15 brokerages maintaining 'hold' ratings. The FDA's decision could ease pressure on Hims & Hers' GLP-1 prospects. The stock's volatility score is high, indicating potential for further price swings.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.